logo

Solar self-supply in 2024

Solar self-supply in 2024

Leave a Comment / Uncategorized / By

During 2024, our photovoltaic plants generated a total of 1,628,153 kWh of energy, contributing significantly to the reduction of our carbon footprint:

  • MOEHS CATALANA S.L.: 506,309 Kwh
  • MOEHS CANTABRA S.L.: 479.156 Kwh
  • MOEHS BCN S.L.: 457.979 Kwh
  • MOEHS IBERICA S.L.: 184.709 Kwh

A very positive environmental impact with a maximum compensation of 814 tons of CO2 eq (442 tons with the current Spanish energy mix).

Equivalent to planting 37,004 trees!

Thanks to the efforts of the entire Moehs Group, we continue to move towards a more sustainable and responsible pharmaceutical industry model.

 

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.